Liraglutide RCT aims to reduce cardiovascular risk markers in women with Polycystic Ovary Syndrome

Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder affecting 5-10% of women of fertile age, characterized by hormonal imbalances and metabolic dysfunction. It is strongly associated with metabolic syndrome, type 2 diabetes, and a significantly increased risk of cardiovascular disease (CVD), including vascular thrombosis. Current management often focuses on symptomatic relief and metabolic control, but specific interventions targeting CVD risk in non-diabetic PCOS women are lacking. Glucagon-like peptide-1 (GLP-1) analogs, like Liraglutide, are known for their beneficial effects on glucose metabolism, weight loss, and cardiovascular outcomes, making them a promising candidate for addressing the elevated CVD risk in this vulnerable population. The study aims to fill this gap by exploring the direct impact of GLP-1 agonism on these critical risk markers.

This study is structured as a Randomized Controlled Trial (RCT) to investigate the impact of a GLP-1 analog, specifically Liraglutide, on cardiovascular risk markers in women with PCOS. The trial aims to enroll 70 women diagnosed with PCOS who are free from diabetes. Participants will be randomized to receive either Liraglutide or a control intervention (likely placebo, as is standard for RCTs). The primary objective is to evaluate a beneficial reduction in risk markers associated with vascular thrombosis and early cardiovascular disease. The abstract does not specify the exact dose, administration route, frequency, or duration of the Liraglutide treatment.

This abstract describes a study protocol and hypothesis, not completed research with results. Therefore, no findings, statistical data, or specific numerical outcomes are available at this stage. The study aims to investigate the effects of Liraglutide on cardiovascular risk markers in women with PCOS, but the actual data collection and analysis are pending.